Drug Trial Radar · NCT06723405
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Feb 13, 2025
Primary completion
Nov 17, 2025
Study completion Nov 17, 2025
Sponsor
- Lead sponsor
- Evommune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
Conditions
- Atopic Dermatitis (AD)
- Eczema
- Eczema Atopic Dermatitis
Interventions
EVO301Biological
Intravenous EVO301
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eczema Area and Severity Index (EASI)Time frame: 12 weeks
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Cornerstone Dermatology
Coorparoo, Australia
Momentum Clinical Research Darlinghurst
Darlinghurst, Australia
Pacific Clinical Research Network (PCRN) Auckland
Auckland, New Zealand
Optimal Clinical Trials North
Auckland, New Zealand
Optimal Clinical Trials
Auckland, New Zealand
Pacific Clinical Research Network (PCRN) Christchurch
Christchurch, New Zealand
Momentum Clinical Research Dunedin
Dunedin, New Zealand
Clinical Trials New Zealand Ltd
Hamilton, New Zealand
Momentum Clinical Research Lower Hutt
Hutt Central, New Zealand
Pacific Clinical Research Network (PCRN) Tasman
Nelson, New Zealand
Momentum Clinical Research Kapiti
Paraparaumu, New Zealand
Momentum Clinical Research Pukekohe
Pukekohe, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.